Skip to Main Content
Table 4—

Age- and sex-adjusted HRs (95% CI) for mortality from CHD, stroke, and CVD, according to levels of IL-6 and CRP in 1,610 men and women

CHD deathsStroke deathsCVD deaths
n 209 84 450 
IL-6    
    Quartile 1 (<1.51 pg/ml) 
    Quartile 2 (1.51–2.27 pg/ml) 1.41 (0.85–2.36) 1.28 (0.63–2.61) 1.30 (0.95–1.80) 
    Quartile 3 (2.27–3.64 pg/ml) 2.00 (1.23–3.26) 1.57 (0.79–3.14) 1.60 (1.18–2.19) 
    Quartile 4 (≥3.64 pg/ml) 3.03 (1.87–4.89) 1.87 (0.93–3.77) 2.32 (1.70–3.15) 
Ptrend <0.0001 0.06 <0.0001 
Per log increase 1.94 (1.57–2.39) 1.34 (0.95–1.89) 1.62 (1.40–1.88) 
Per SD in log increase* 1.58 (1.37–1.83) 1.22 (0.97–1.55) 1.40 (1.26–1.54) 
    Adjusted for metabolic syndrome 1.56 (1.35–1.81) 1.19 (0.94–1.52) 1.38 (1.25–1.53) 
    Additionally adjusted for CRP 1.46 (1.23–1.74) 1.27 (0.96–1.67) 1.38 (1.23–1.56) 
    Fully adjusted 1.47 (1.24–1.76) 1.20 (0.90–1.58) 1.35 (1.19–1.52) 
    No history of CHD or stroke 1.67 (1.42–1.97) 1.15 (0.89–1.49) 1.43 (1.28–1.60) 
    History of CHD or stroke 1.18 (0.85–1.64) 1.73 (0.91–3.30) 1.13 (0.88–1.45) 
    P value for interaction 0.05 0.29 0.06 
CRP    
    Quartile 1 (<0.84 mg/l) 
    Quartile 2 (0.84–1.73 mg/l) 1.32 (0.85–2.04) 0.79 (0.43–1.44) 1.03 (0.78–1.35) 
    Quartile 3 (1.73–3.90 mg/l) 1.47 (0.96–2.26) 0.79 (0.43–1.47) 1.15 (0.88–1.51) 
    Quartile 4 (≥3.90 mg/l) 2.13 (1.41–3.21) 1.08 (0.60–1.94) 1.40 (1.07–1.83) 
Ptrend 0.0002 0.80 0.008 
Per log increase 1.36 (1.20–1.54) 1.04 (0.84–1.28) 1.17 (1.07–1.28) 
Per SD in log increase* 1.40 (1.22–1.61) 1.04 (0.83–1.31) 1.19 (1.08–1.32) 
    Adjusted for metabolic syndrome 1.37 (1.18–1.58) 0.99 (0.78–1.26) 1.16 (1.05–1.28) 
    Additionally adjusted for IL-6 1.13 (0.96–1.33) 0.89 (0.68–1.16) 0.99 (0.89–1.11) 
    Fully adjusted 1.12 (0.95–1.32) 0.92 (0.70–1.20) 1.00 (0.90–1.12) 
    No history of CHD or stroke 1.51 (1.28–1.77) 1.01 (0.79–1.31) 1.24 (1.11–1.38) 
    History of CHD or stroke 1.03 (0.78–1.36) 1.08 (0.62–1.88) 0.96 (0.78–1.19) 
    P value for interaction 0.02 0.89 0.03 
CHD deathsStroke deathsCVD deaths
n 209 84 450 
IL-6    
    Quartile 1 (<1.51 pg/ml) 
    Quartile 2 (1.51–2.27 pg/ml) 1.41 (0.85–2.36) 1.28 (0.63–2.61) 1.30 (0.95–1.80) 
    Quartile 3 (2.27–3.64 pg/ml) 2.00 (1.23–3.26) 1.57 (0.79–3.14) 1.60 (1.18–2.19) 
    Quartile 4 (≥3.64 pg/ml) 3.03 (1.87–4.89) 1.87 (0.93–3.77) 2.32 (1.70–3.15) 
Ptrend <0.0001 0.06 <0.0001 
Per log increase 1.94 (1.57–2.39) 1.34 (0.95–1.89) 1.62 (1.40–1.88) 
Per SD in log increase* 1.58 (1.37–1.83) 1.22 (0.97–1.55) 1.40 (1.26–1.54) 
    Adjusted for metabolic syndrome 1.56 (1.35–1.81) 1.19 (0.94–1.52) 1.38 (1.25–1.53) 
    Additionally adjusted for CRP 1.46 (1.23–1.74) 1.27 (0.96–1.67) 1.38 (1.23–1.56) 
    Fully adjusted 1.47 (1.24–1.76) 1.20 (0.90–1.58) 1.35 (1.19–1.52) 
    No history of CHD or stroke 1.67 (1.42–1.97) 1.15 (0.89–1.49) 1.43 (1.28–1.60) 
    History of CHD or stroke 1.18 (0.85–1.64) 1.73 (0.91–3.30) 1.13 (0.88–1.45) 
    P value for interaction 0.05 0.29 0.06 
CRP    
    Quartile 1 (<0.84 mg/l) 
    Quartile 2 (0.84–1.73 mg/l) 1.32 (0.85–2.04) 0.79 (0.43–1.44) 1.03 (0.78–1.35) 
    Quartile 3 (1.73–3.90 mg/l) 1.47 (0.96–2.26) 0.79 (0.43–1.47) 1.15 (0.88–1.51) 
    Quartile 4 (≥3.90 mg/l) 2.13 (1.41–3.21) 1.08 (0.60–1.94) 1.40 (1.07–1.83) 
Ptrend 0.0002 0.80 0.008 
Per log increase 1.36 (1.20–1.54) 1.04 (0.84–1.28) 1.17 (1.07–1.28) 
Per SD in log increase* 1.40 (1.22–1.61) 1.04 (0.83–1.31) 1.19 (1.08–1.32) 
    Adjusted for metabolic syndrome 1.37 (1.18–1.58) 0.99 (0.78–1.26) 1.16 (1.05–1.28) 
    Additionally adjusted for IL-6 1.13 (0.96–1.33) 0.89 (0.68–1.16) 0.99 (0.89–1.11) 
    Fully adjusted 1.12 (0.95–1.32) 0.92 (0.70–1.20) 1.00 (0.90–1.12) 
    No history of CHD or stroke 1.51 (1.28–1.77) 1.01 (0.79–1.31) 1.24 (1.11–1.38) 
    History of CHD or stroke 1.03 (0.78–1.36) 1.08 (0.62–1.88) 0.96 (0.78–1.19) 
    P value for interaction 0.02 0.89 0.03 
*

SD in log increase (IL-6 2.81 in women and 2.61 in men; CRP 5.24 in women and 5.15 in men).

Fully adjusted model includes age, sex, metabolic syndrome, CRP, IL-6, LDL cholesterol, smoking, exercise, alcohol consumption, menopausal status, and HRT use.

1,399 participants without prevalent disease (deaths from CHD = 152, stroke = 69, and CVD = 345); 211 participants with prevalent disease (deaths from CHD = 57, stroke = 16, and CVD = 105).

Close Modal

or Create an Account

Close Modal
Close Modal